Abstract:Objective To investigate the mRNA expression of SMAD9 in lung adenocarcinoma, and its relationship with clinicopathological parameters, survival and prognosis, so as to provide some valuable references for the screening and postoperative survival. Methods The expression of SMAD9 in tumor tissues (510 cases) and adjacent normal tissues (59 cases) of lung adenocarcinoma patients and its relationship with clinicopathological parameters and postoperative survival were analyzed based on the Cancer Genome Atlas (TCGA) database. The expression of SMAD9 in tumor tissues and adjacent normal tissues of lung adenocarcinoma patients, HBE malignant transformed cells induced by 3-MCA and lung adenocarcinoma cells were detected by quantitative real-time RT-PCR (qRT-PCR) and Western blotting. The effect of SMAD9 overexpression and interference on cell proliferation was detected by CCK-8 assay. Results The mRNA expression analysis of SMAD9 in TCGA database showed that the expression of SMAD9 was significantly lower in lung adenocarcinoma than adjacent normal tissues (P < 0.01). The results of qRT-PCR and Western blotting also showed that the expression of SMAD9 was significantly down-regulated in 3-MCA-induced HBE malignant transformed cells and lung adenocarcinoma tissues and cell lines (P < 0.05). The down-regulation of SMAD9 expression was closely correlated with N grade and tumor grade (P < 0.05). ROC curve analysis indicated that the mRNA expression of SMAD9 was a sensitive indicator of lung adenocarcinoma (AUC=0.903, 95%CI=0.868~0.938, P < 0.001). Kaplan-Meier analysis displayed that the survival time of patients with low expression of SMAD9 was significantly shorter than those with high expression (P < 0.05). Overexpression of SMAD9 inhibited the proliferation of lung adenocarcinoma cells (P < 0.01), and the proliferation of HBE cells was significantly enhanced after interfering with SMAD9 expression as compared with the control cells (P < 0.01). Conclusion SMAD9 gene expression is down-regulated in the incidence and development of lung adenocarcinoma. The expression of SMAD9 may be of great value for the screening and postoperative survival of lung adenocarcinoma patients.

Knockdown of SMAD3 Inhibits the Growth and Enhances the Radiosensitivity of Lung Adenocarcinoma Via P21 in Vitro and in Vivo.

Knockdown of SMAD3 Inhibits the Growth and Enhances the Radiosensitivity of Lung Adenocarcinoma via p21/Cell Cycle in vitro and in vivo

Identification of ATAD3A As a Key Regulator in Non-Small Cell Lung Cancer by Promoting STAT3-induced Cell Proliferation and Tumor Angiogenesis

NPM3 As a Novel Oncogenic Factor and Poor Prognostic Marker Contributes to Cell Proliferation and Migration in Lung Adenocarcinoma

SMAD3 Silencing Enhances DNA Damage in Radiation Therapy by Interacting with MRE11-RAD50-NBS1 Complex in Glioma.

MLLT3 knockdown suppresses proliferation and cell mobility in human lung adenocarcinoma

Single-cell transcriptomic sequencing data reveal aberrant DNA methylation in SMAD3 promoter region in tumor-associated fibroblasts affecting molecular mechanism of radiosensitivity in non-small cell lung cancer

MicroRNA-32-5p Inhibits Epithelial-Mesenchymal Transition and Metastasis in Lung Adenocarcinoma by Targeting SMAD Family 3.

PIG3 downregulation enhances the radio sensitivity of NSCLC cells by promoting G2/M cell cycle arrest and apoptosis

MUC3A Promotes Non-Small Cell Lung Cancer Progress Via Activating NFκB Pathway and Attenuates Radiosensitivity

Expression and clinical significance of SMAD9 in lung adenocarcinoma

(E)-SIS3 Suppressed Osteosarcoma Progression Via Promoting Cell Apoptosis, Arresting Cell Cycle, and Regulating the Tumor Immune Microenvironment

Inhibition mechanism of lung cancer cell metastasis through targeted regulation of Smad3 by miR-15a

Targeting Smad2 and Smad3 by Mir-136 Suppresses Metastasis-Associated Traits of Lung Adenocarcinoma Cells

Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells.

Sirt3 is a tumor suppressor in lung adenocarcinoma cells.

Sirt3 Promoted DNA Damage Repair and Radioresistance Through ATM-Chk2 in Non-small Cell Lung Cancer Cells

MiR-145 Modulates the Radiosensitivity of Non-Small Cell Lung Cancer Cells by Suppression of TMOD3.

Mir-212-5p Exerts Tumor Promoter Function by Regulating the Id3/PI3K/Akt Axis in Lung Adenocarcinoma Cells.

Abstract 4167: MUC3A Promotes Lung Cancer Progress Via Activating NFκB Pathway and Attenuates Radiosensitivity

SMYD3 Overexpression Indicates Poor Prognosis and Promotes Cell Proliferation, Migration and Invasion in Non‑small Cell Lung Cancer.